SG11201900681SA - Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors - Google Patents
Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitorsInfo
- Publication number
- SG11201900681SA SG11201900681SA SG11201900681SA SG11201900681SA SG11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- hyderabad
- serene
- life sciences
- avenue
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960003530 donepezil Drugs 0.000 abstract 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 241000269435 Rana <genus> Species 0.000 abstract 1
- 239000004783 Serene Substances 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028166 | 2016-08-18 | ||
| PCT/IB2017/054938 WO2018033847A1 (fr) | 2016-08-18 | 2017-08-14 | Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900681SA true SG11201900681SA (en) | 2019-02-27 |
Family
ID=59887325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900681SA SG11201900681SA (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10603323B2 (fr) |
| EP (1) | EP3500253B1 (fr) |
| JP (1) | JP6734470B2 (fr) |
| KR (1) | KR102039585B1 (fr) |
| CN (1) | CN109640975B (fr) |
| AU (1) | AU2017313427B2 (fr) |
| CA (1) | CA3033039C (fr) |
| CY (1) | CY1123238T1 (fr) |
| DK (1) | DK3500253T3 (fr) |
| EA (1) | EA032957B1 (fr) |
| ES (1) | ES2810983T3 (fr) |
| HR (1) | HRP20201262T1 (fr) |
| HU (1) | HUE052003T2 (fr) |
| IL (1) | IL264406B (fr) |
| LT (1) | LT3500253T (fr) |
| MA (1) | MA45990B1 (fr) |
| MD (1) | MD3500253T2 (fr) |
| ME (1) | ME03812B (fr) |
| MX (1) | MX374114B (fr) |
| NZ (1) | NZ750150A (fr) |
| PL (1) | PL3500253T3 (fr) |
| PT (1) | PT3500253T (fr) |
| RS (1) | RS60669B1 (fr) |
| SG (1) | SG11201900681SA (fr) |
| SI (1) | SI3500253T1 (fr) |
| SM (1) | SMT202000435T1 (fr) |
| WO (1) | WO2018033847A1 (fr) |
| ZA (1) | ZA201900467B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52850B1 (fr) * | 2018-05-31 | 2025-03-28 | Suven Life Sciences Limited | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2011153723A (ru) * | 2009-06-10 | 2013-07-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения |
| WO2012114348A1 (fr) * | 2011-02-23 | 2012-08-30 | Suven Life Sciences Limited | Nouveaux composés utilisés en tant que ligands des récepteurs h3 histaminiques |
| FR2974729B1 (fr) | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| CN105764510A (zh) | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
-
2017
- 2017-08-14 SM SM20200435T patent/SMT202000435T1/it unknown
- 2017-08-14 WO PCT/IB2017/054938 patent/WO2018033847A1/fr not_active Ceased
- 2017-08-14 SG SG11201900681SA patent/SG11201900681SA/en unknown
- 2017-08-14 SI SI201730360T patent/SI3500253T1/sl unknown
- 2017-08-14 PT PT177682341T patent/PT3500253T/pt unknown
- 2017-08-14 KR KR1020197007056A patent/KR102039585B1/ko active Active
- 2017-08-14 AU AU2017313427A patent/AU2017313427B2/en active Active
- 2017-08-14 PL PL17768234T patent/PL3500253T3/pl unknown
- 2017-08-14 DK DK17768234.1T patent/DK3500253T3/da active
- 2017-08-14 ME MEP-2020-167A patent/ME03812B/fr unknown
- 2017-08-14 EP EP17768234.1A patent/EP3500253B1/fr active Active
- 2017-08-14 EA EA201990480A patent/EA032957B1/ru unknown
- 2017-08-14 CN CN201780049311.9A patent/CN109640975B/zh active Active
- 2017-08-14 US US16/320,949 patent/US10603323B2/en active Active
- 2017-08-14 NZ NZ750150A patent/NZ750150A/en unknown
- 2017-08-14 CA CA3033039A patent/CA3033039C/fr active Active
- 2017-08-14 HU HUE17768234A patent/HUE052003T2/hu unknown
- 2017-08-14 MX MX2019001696A patent/MX374114B/es active IP Right Grant
- 2017-08-14 MA MA45990A patent/MA45990B1/fr unknown
- 2017-08-14 RS RS20200949A patent/RS60669B1/sr unknown
- 2017-08-14 ES ES17768234T patent/ES2810983T3/es active Active
- 2017-08-14 JP JP2019506640A patent/JP6734470B2/ja active Active
- 2017-08-14 MD MDE20190714T patent/MD3500253T2/ro unknown
- 2017-08-14 HR HRP20201262TT patent/HRP20201262T1/hr unknown
- 2017-08-14 LT LTEP17768234.1T patent/LT3500253T/lt unknown
-
2019
- 2019-01-22 IL IL264406A patent/IL264406B/en active IP Right Grant
- 2019-01-23 ZA ZA2019/00467A patent/ZA201900467B/en unknown
-
2020
- 2020-08-05 CY CY20201100725T patent/CY1123238T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201900269XA (en) | Channel sensing for independent links | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |